Abnova

Abnova is one of the world’s largest antibody manufacturer.

Abnova provide total solutions to researchers in multidisciplinary areas.
-Biotinylated Bioactive Proteins
-ELISA & Assay Kits
-CellTx™ Cell Therapy
-Neuroscience Bioreagents
-NanoAb™ VHH antibody platform
-nanoCAR-T mRNA

1. VHH Bispecific Ab

   The bispecific antibody (BsAb) is a type of recombinant antibody engineered to simultaneously bind to two different antigens or epitopes, facilitating various applications, such as redirecting T cells to tumor cells, dual targeting of disease mediators, blocking multiple signaling pathways, dual targeting of disease mediators, and delivering payloads to targeted sites. Abnova offers custom services of four types of VHH bispecific antibodies: Bispecific VHH (No Fc) (nanoBiTE™), Bispecific VHH Mouse IgG, Bispecific VHH Rabbit IgG, and Bispecific VHH Human IgG. Traditional bispecific antibodies have inherent hydrophobic interactions in the VH and VL domains of engineered antibodies, limiting stability and solubility, and resulting in aggregation and mispairing of V domains. In contrast, VHH bispecific antibodies have a completely hydrophilic surface and do not bind light chains, allowing them to be easily linked into dimers by genetically fusing a second VHH antibody via a linker peptide to the N-terminus of a heavy-chain antibody. Such VHH-based bispecific antibodies show the advantages of small size, high solubility, high stability, and excellent tissue penetration in vivo.

2. nanoCAR-T mRNA

   Abnova provides a nanoCAR-T mRNA service that advances CAR-T cell therapy by integrating its NanoAb™ VHH antibody platform, mRNA IVT technology, and lipid nanoparticle (LNP) delivery. This approach allows precise ex vivo delivery of CAR instructions to T cells via mRNA encapsulated in ionizable lipid nanoparticles. Unlike conventional CAR-T therapies that use single-chain variable fragments (scFv) from monoclonal antibodies, Abnova incorporates smaller VHH antibodies for high affinity antigen targeting. This allows access to cryptic antigen epitopes often missed by traditional antibodies and improve tissue penetration into the highly complex tumor microenvironment. The smaller VHH antibodies also enable the construction of bispecific CAR-T to expand its cancer-killing options.

3. FFPE Tumor Tissue DNA

   We provideresearchers requiring formalin-fixed, paraffin-embedded (FFPE) tumor tissue DNA molecular characterization. Our capability is supported by a fully automated platform for FFPE tissue DNA extraction, multiplex PCR-based targeted enrichment, library preparation, next-generation sequencing, and gene mutation analysis. This robust workflow increases traceability and reproducibility and improves the quality and efficacy of cancer mutation studies. Targeted sequencing of actionable mutations has important implications for cancer diagnosis, prognosis, treatment, and monitoring in the new era of personalized medicine.

4. In Situ Hybridization (ISH)

   In Situ Hybridization (ISH) encompasses the use of CISH (Chromogenic In Situ Hybridization), traditional FISH (Fluorescence In Situ Hybridization) probes, and a new generation of mutaFISH™ (mutation-specific FISH) probes and RollFISH (Rolling FISH) probes for the detection of chromosome aneuploidy and split, DNA gene amplification and translocation, mRNA single nucleotide variant, splice variant, and wild type, and miRNA in cells and tissues. Customers can provide their probes of interest or choose from Abnova’s large catalog collection of ready-to-go CISH, FISH, mutaFISH™, and RollFISH probes. New probes can also be designed and produced for the customers upon request.